TY  - JOUR 
AU  - Valladares Ayerbes, Manuel
PY  - 2011
SN  - 0167-6997
UR  - http://hdl.handle.net/20.500.11940/2745
LA  - eng
TI  - A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
DO  - 10.1007/s10637-010-9392-8
T2  - INVESTIGATIONAL NEW DRUGS
M2  - 1021
VL  - 29
ER  -